Syndax Pharmaceuticals SNDX Business Segments — Other Research And Development Expense

Similar metrics at other companies

DNLITherapeutics Segment — Research and Development Expense

$103.85M-10.7%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

VRTXPharmaceuticals — Development expenses

$756.6M-2.2%

RAPPOther Costs — Research And Development Expense

$1.97M+24.7%

SRPTAll Other Segments — Other Research And Development Expense

$18.67M-34.4%

Questions, answered.

What is Syndax Pharmaceuticals's business segments — other research and development expense?

Syndax Pharmaceuticals (SNDX) reported business segments — other research and development expense of $162K in Q1 2026.

How has Syndax Pharmaceuticals's business segments — other research and development expense changed year-over-year?

Syndax Pharmaceuticals's business segments — other research and development expense decreased by 82.4% year-over-year, from $921K to $162K.

What is the long-term trend for Syndax Pharmaceuticals's business segments — other research and development expense?

Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — other research and development expense has grown at a -13.1% compound annual growth rate (CAGR), from $6.33M to $4.15M.

What does business segments — other research and development expense mean?

This encompasses ancillary research and development costs not directly tied to primary clinical trials, such as early-stage discovery, laboratory supplies, or specialized research equipment. It provides insight into the company's commitment to maintaining a pipeline of future therapeutic candidates. High spending here indicates a focus on long-term innovation and pipeline diversification.